Strand Therapeutics

@Nasdaq helped us in celebrating our Series B with a billboard in the heart of Time Square! Thank you to our friends at Nasdaq for your support on our mission to create cures for patients!

Our co-founder and CEO @DrSynbio testified before the Select Committee on China this week on a key question: when clinical trials move abroad, who loses? Jake says American patients do, and so does American science. He advocated for a targeted policy fix that would keep trials at home, expand patient access, and restore our competitive edge.

@jasonlukemd @sitcancer @ASTCT Full paper: astctjournal.org/article/S2666-…

Congratulations to our CMO, @jasonlukemd, on co-leading a white paper on expanding cell therapies to solid tumors in collaboration with @sitcancer and @ASTCT. The work reflects the cross-disciplinary thinking at the heart of what we're building at Strand. Link in next post.

Happy International Women's Day! Strands wore purple on Friday to recognize and celebrate the accomplishments of women in STEM!

The nation that leads in early-stage biotech will shape global health, set regulatory standards, and control critical supply chains. Now, that leadership is leaving the US. Strand CEO and Co-founder @DrSynbio wrote an op-ed in @washingtonpost about why this is happening and how to stop it: washingtonpost.com/opinions/2026/…

300M people. 7K+ conditions. Fewer than 5% with approved treatments. Many rare diseases are driven by underlying genetic causes that targeted medicine could address. Strand is building programmable mRNA that activates only in specific cells. It started with cancer, but the same platform could change what's possible in rare disease. #RareDiseaseDay #ShowYourStripes

February is #CancerPreventionMonth. Prevention and early detection save lives. And for patients who've exhausted standard options, better treatments can too. That's what drives our work at Strand, and what keeps us believing the hardest cancers can be fought.

The next frontier of mRNA isn't just delivering a message. It's programming one. CEO @DrSynbio joins @biospace's Denatured to discuss how mRNA therapeutics are taking the next step, starting with cancer and designed to go beyond. 🎧biospace.com/business/progr…

Strand wishes everyone a safe and exciting Superbowl weekend! Congratulations to Eloise, Chase, and Kendall for winning our Patriots Superbowl Trivia and Go Pats!  🏈🏆

What a week at #JPM26. CEO @DrSynbio's presentation sparked exactly the kind of conversations we hoped to have around scaling programmable mRNA and the future of genetic medicine. Thanks to our investors, partners, and team for making it such a productive week. Now, time to get back to work.

At #JPM26 this week, Strand Therapeutics CEO @DrSynbio presents Wed, Jan 14 | 10:30 AM PT. He’ll cover clinical results and Strand’s approach to programming conditional protein expression into mRNA, plus what’s next after a milestone year of validation and platform expansion. More information: businesswire.com/news/home/2025… See you there.

2025 was a transformative year for Strand. ✔️ First-in-human data showing tumor-selective activation ✔️ Expansion to systemic delivery ✔️ $153M Series B Now, we’re moving into 2026 with clinical momentum and a platform ready to define what's next in genetic medicine.

Super excited for our @StrandTx @DrSynbio presentation on the main #JPM26 program Wed Jan 14-1030 PT. Hope to see everyone in San Fran! Dance card is pretty full but love to connect w any interested in repRNA IL-12, circRNA in vivo CART or RNA Rx for cancer, autoimmunity & beyond

Wishing everyone a happy and healthy holiday from the team at Strand Therapeutics!

Catch us at #JPM26, where Strand Therapeutics CEO @DrSynbio will be presenting on Wednesday, January 14, 2026, at 10:30 AM PT. Looking forward to connecting with innovators and industry leaders in San Francisco. More information: businesswire.com/news/home/2025…

“We are standing on the precipice of the future of genetic medicines.” Strand Therapeutics CEO @DrSynbio joined @ashleevance on @corememory to share how Strand is building mRNA therapeutics that sense their environment and activate only in target cells, like cancer. Learn how mRNA is shaping the infrastructure of medicine and what’s coming next. Full episode: corememory.com/p/theyre-attac…

We're excited to welcome @JebKeiper to Strand's Board as an independent Director! Strand gains invaluable expertise from Jeb, whose proven track record as former CEO of Nimbus Therapeutics encompasses preclinical R&D innovation, clinical development, and global business development and licensing. With him on board, we’re driving the future of genetic medicines forward. Read more: businesswire.com/news/home/2025…

Excited our @StrandTx musician CMO @jasonlukemd is being awarded as a “Champion of @sitcancer" #SITC25 & playing trumpet in the Checkpoints band! Our team is excited to rock next gen #immunotherapy advances with multiple field leading, novel treatments for #cancer!

We’re honored to announce that Strand Therapeutics has been awarded the BioTech Startup of the Year award from BioTech Breakthrough! Thanks to the team at BioTech Breakthrough for highlighting the dedication of our team as we continue to forge a new path in mRNA therapeutics! finance.yahoo.com/news/5th-annua…

Check out the press release here! Congratulations Prashant and Ethan! businesswire.com/news/home/2025…

We’re excited to announcethe promotion of Prashant Nambiar to Chief Scientific Officer and appointment of Ethan Cash to SVP of Program Development! As Strand’s research continues evolve towards clinical trials, these appointments will be vital in securing our success.